Swiss Pharma Report issue

Academic/Hospital Phase 1 Phase 2
Status: Acquired by Covance (2009) → now LabCorp (2014)

Organization Overview

First Clinical Trial
2003
NCT00189956
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Swiss Pharma Contract | SWISS PHARMA CONTRACT LTD

Active Ingredients

Drugs in Phase 2 Trials (1)

smallpox vaccine, live attenuated (imvamune) (1 trial)

Drugs in Phase 1 Trials (2)

finafloxacin (xtoro) (1 trial)

friulimicin b (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cellulitis (Phase 1)

Communicable Diseases (Phase 1)

Helicobacter Infections (Phase 1)

Infections (Phase 1)

Pneumonia (Phase 1)

Skin Diseases, Infectious (Phase 1)

Smallpox (Phase 2)

Staphylococcal Skin Infections (Phase 1)

Urinary Tract Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3